Panel discussion spotlights COVID-19 R&D

July 19, 2022- 
The DSI’s career panel series continued on June 28 to highlight some of LLNL’s COVID-19 research projects. Three data scientists—Emilia Grzesiak, Derek Jones, and Priyadip Ray—joined moderator and data scientist Stewart He to talk about their work in drug screening, protein–drug compounds, antibody–antigen sequence analysis, and risk factor identification. He, who earned a PhD in Computer...

UC Merced students work with LLNL mentors on potential new drugs to combat COVID-19

June 30, 2022- 
Students from the University of California, Merced worked with mentors at LLNL to identify drug compounds that could be used to treat COVID-19 during a two-week Data Science Challenge (DSC) that concluded on June 6. For the first time in the DSC series since the COVID-19 pandemic began in 2020, Lab mentors visited the college campus to provide in-person guidance for five teams of UC Merced...

LLNL’s Brase discusses advances by ATOM in accelerating drug discovery pipeline

June 7, 2022- 
The private-public Accelerating Therapeutic Opportunities in Medicine (ATOM) consortium is showing “significant” progress in demonstrating that HPC and M) tools can speed up the drug discovery process, said Jim Brase, ATOM co-lead and LLNL’s deputy associate director for data science. The consortium currently boasts more than a dozen member organizations, including national laboratories...

Kevin McLoughlin applies computational biology to complex problems

May 17, 2022- 
Kevin McLoughlin has always been fascinated by the intersection of computing and biology. His LLNL career encompasses award-winning microbial detection technology, a COVID-19 antiviral drug design pipeline, and work with the ATOM consortium. The appeal for him in these projects lies at the intersection of computing and biology. “I love finding ways to visualize data that reveal relationships...

Machine learning model finds COVID-19 risks for cancer patients

March 10, 2022- 
A new study by researchers at LLNL and the University of California, San Francisco, looks to identify cancer-related risks for poor outcomes from COVID-19. Analyzing one of the largest databases of patients with cancer and COVID-19, the team found previously unreported links between a rare type of cancer—as well as two cancer treatment-related drugs—and an increased risk of hospitalization...

LLNL team models COVID-19 disease progression and identifies risk factors

Feb. 15, 2022- 
An LLNL team has developed a comprehensive dynamic model of COVID-19 disease progression in hospitalized patients, finding that risk factors for complications from the disease are dependent on the patient’s disease state. Using a machine learning algorithm on a dataset of electronic health records from more than 1,300 hospitalized COVID-19 patients with ProMedica — the largest health care...

LLNL joins Human Vaccines Project to accelerate vaccine development and understanding of immune response

Oct. 21, 2021- 
LLNL has joined the international Human Vaccines Project (HVP), bringing Lab expertise and computing resources to the consortium to aid development of a universal coronavirus vaccine and improve understanding of immune response. The HVP is a nonprofit, public-private partnership with a mission to decode the human immune system and accelerate the development of vaccines and immunotherapies...

Tackling the COVID-19 pandemic

Oct. 11, 2021- 
To help the U.S. fight the COVID-19 pandemic, LLNL did what it does best: quickly bring together interdisciplinary teams and diverse technologies to address urgent national challenges. This effort includes applying advanced high-performance computing resources to biological research and anayzing complicated computer models and enormous datasets. Read more in Science & Technology Review.

COVID-19 detection and analysis with Nisha Mulakken (VIDEO)

June 7, 2021- 
LLNL biostatistician Nisha Mulakken has enhanced the Lawrence Livermore Microbial Detection Array (LLMDA) system with detection capability for all variants of SARS-CoV-2. The technology detects a broad range of organisms—viruses, bacteria, archaea, protozoa, and fungi—and has demonstrated novel species identification for human health, animal health, biodefense, and environmental sampling...

COVID-19 HPC Consortium reflects on past year

April 1, 2021- 
COVID-19 HPC Consortium scientists and stakeholders met virtually on March 23 to mark the consortium’s one-year anniversary, discussing the progress of research projects and the need to pursue a broader organization to mobilize supercomputing access for future crises. The White House announced the launch of the public-private consortium, which provides COVID-19 researchers with free access to...

Model for COVID-19 drug discovery a Gordon Bell finalist

Nov. 17, 2020- 
A machine learning model developed by a team of LLNL scientists to aid in COVID-19 drug discovery efforts is a finalist for the Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research. Using Sierra, the world’s third fastest supercomputer, LLNL scientists produced a more accurate and efficient generative model to enable COVID-19 researchers to produce novel compounds...

COVID-19 research goes public through new portal

May 18, 2020- 
A new online data portal is making available to the public a wealth of data LLNL scientists have gathered from their ongoing COVID-19 molecular design projects, particularly the computer-based “virtual” screening of small molecules and designed antibodies for interactions with the SARS-CoV-2 virus for drug design purposes. The portal houses a wealth of data LLNL scientists have gathered from...

New ML platform generates novel COVID-19 antibody sequences for experimental testing

May 1, 2020- 
LLNL researchers have identified an initial set of therapeutic antibody sequences, designed in a few weeks using machine learning and supercomputing, aimed at binding and neutralizing SARS-CoV-2, the virus that causes COVID-19. The research team is performing experimental testing on the chosen antibody designs. Read more at LLNL News.

Upgrades for LLNL supercomputer from AMD, Penguin Computing aid COVID-19 research

April 21, 2020- 
Under a new agreement, AMD will supply upgraded graphics accelerators for LLNL’s Corona supercomputing cluster, expected to nearly double the system’s peak compute power. The system will be used by scientists through the public/private COVID-19 HPC Consortium, and by LLNL researchers, who are working on discovering potential antibodies and anti-viral compounds for SARS-CoV-2, the virus that...

LLNL creates web resources to aid in fight against COVID-19

March 30, 2020- 
LLNL is fully committed to helping protect the U.S. from COVID-19 and to speed the recovery of those affected. As a world-class research institute, we have considerable infrastructure, unique research capabilities and a dedicated team of scientists and engineers supporting the fight against the COVID-19 pandemic. Our current COVID-19 research and response activities are focused on four broad...

Lab antibody, anti-viral research aids COVID-19 response

March 26, 2020- 
LLNL scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease. Armed with the virus’ predicted 3D structure and a few antibodies known to bind and neutralize SARS, an LLNL team led by Daniel Faissol and...

New partnership to unleash U.S. supercomputing resources in the fight against COVID-19

March 26, 2020- 
The White House announced the launch of the COVID-19 High Performance Computing Consortium to provide COVID-19 researchers worldwide with access to the world’s most powerful high performance computing resources that can significantly advance the pace of scientific discovery in the fight to stop the virus. Read more at LLNL News.